Synthesis, biological evaluation and molecular modelling studies of novel ACD- and ABD-ring steroidomimetics as inhibitors of CYP17

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 1, 2008, Pages 267-273

  Pinto Bazurco Mendieta, Mariano A E ^a   Negri, Matthias ^a   Jagusch, Carsten ^a   Hille, Ulrike E ^a   Müller Vieira, Ursula ^b   Schmidt, Dirk ^c   Hansen, Klaus ^c   Hartmann, Rolf W ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b Pharmacelsus CRO   (Germany)

^c Schwarz Pharma AG   (Germany)

Author keywords

17 hydroxylase 17,20 lyase (CYP17) inhibitors; Docking studies; Hepatic CYPs; Prostate cancer; Steroidomimetics

Indexed keywords

3 PYRIDYL DERIVATIVE; 4 PYRIDYL DERIVATIVE; ABIRATERONE; ABIRATERONE DERIVATIVE; CYTOCHROME P450 11B1; CYTOCHROME P450 17; CYTOCHROME P450 17 INHIBITOR; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; UNCLASSIFIED DRUG;

ARTICLE; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; INHIBITION KINETICS; LIGAND BINDING; MOLECULAR MODEL; NONHUMAN; PROSTATE CANCER;

BIOMIMETIC MATERIALS; ENZYME INHIBITORS; HETEROCYCLIC COMPOUNDS; HUMANS; LIVER; MODELS, MOLECULAR; NAPHTHALENES; PROGESTERONE; STEROID 17-ALPHA-HYDROXYLASE;

EID: 37549041702     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.10.079     Document Type: Article

References (35)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. CA Cancer J. Clin. 57 (2007) 43
2. Huhtaniemi I., Nikula H., Parvinen M., and Rannikko S. Am. J. Clin. Oncol. 11 (1988) 11
3. Labrie F., Dupont A., Belanger A., Lefebvre F.A., Cusan L., Monfette G., Laberge J.G., Emond J.P., Raynaud J.P., Husson J.M., and Fazekas A.T. J. Steroid Biochem. 19 (1983) 999
4. Nnane I.P., Long B.J., Ling Y.-Z., Grigoryev D.N., and Brodie A.M. Br. J. Cancer 83 (2000) 74
5. Schuurmans A.L.G., Bolt J., Veldscholte J., and Mulder E. J. Steroid Biochem. Mol. Biol. 37 (1990) 849
6. Harris K.A., Weinberg V., Bok R.A., Kakefuda M., and Small E.J. J. Urol. 168 (2002) 542
7. Eklund J., Kozloff M., Vlamakis J., Starr A., Mariott M., Gallot L., Jovanovic B., Schilder L., Robin E., Pins M., and Bergan R.C. Cancer 106 (2006) 2459
8. Small E.J., Halabi S., Dawson N.A., Stadler W.M., Rini B.I., Picus J., Gable P., Torti F.M., Kaplan E., and Vogelzang N.J. J. Clin. Oncol. 22 (2004) 1025
9. Cougar Biotechnology, Inc. http://www.cougarbiotechnology.com/docs/052107CougarPhaseIIAUAAnnualMeeting2007.pdf accessed: 05/31/2007.
10. Kolar N.W., Swart A.C., Mason J.I., and Swart P.J. J. Biotechnol. 129 (2007) 635
11. Samer H., Ehmer P.B., Barassin S., Batzl-Hartmann C., and Hartmann R.W. J. Steroid Biochem. Mol. Biol. 84 (2003) 555
12. Haidar S., and Hartmann R.W. In: Smith H.J., and Simons C. (Eds). Enzymes and their Inhibition, Drug Development (2005), CRC Press, Boca Raton 241
13. Matsunaga N., Kaku T., Itoh F., Tanaka T., Hara T., Miki H., Iwasaki M., Aono T., Yamaoka M., and Kusaka M. Bioorg. Med. Chem. 12 (2004) 2251
14. Hartmann, R. W.; Wachall, B.; Yoshihama, M.; Nakakoshi, M.; Nomoto, S.; Ikeda, Y. WO018075, 1999.
15. Wachall B.G., Hector M., Zhuang Y., and Hartmann R.W. Bioorg. Med. Chem. 7 (1999) 1913
16. Zhuang Y., Wachall B.G., and Hartmann R.W. Bioorg. Med. Chem. 8 (2000) 1245
17. Leroux F., Hutschenreuter T.U., Charrière C., Scopelliti R., and Hartmann R.W. Helv. Chim. Acta 86 (2003) 2671
18. Schenkman J.B., Sligar S.G., and Cinti D.L. Pharmacol. Ther. 12 (1981) 43
19. Miyaura N., and Suzuki A. Chem. Rev. 95 (1995) 2457
20. Tang Y., Dong Y., and Vennerstrom J.L. Synthesis 15 (2004) 2540
21. Hutschenreuter T.U., Ehmer P.B., and Hartmann R.W.J. Enzyme Inhib. Med. Chem. 18 (2004) 17
22. Ehmer P.B., Jose J., and Hartmann R.W. J. Steroid Biochem. Mol. Biol. 75 (2000) 57
23. Sergejew T.F., and Hartmann R.W. J. Enzyme Inhib. 8 (1994) 113
24. Manga N., Duhhy J.C., Rowe P.H., and Cronin M.T.D. SAR QSAR Environ. Res. 16 (2005) 43
25. Hodgson J. Nat. Biotech. 19 (2001) 722
26. For hepatic CYP inhibition data the recombinantly expressed enzymes from baculovirus-infected insect microsomes (Supersomes) were used and the manufacturer's instructions (www.gentest.com) were followed.
27. 14C]-11-deoxycorticosterone was applied (Ref.27).
28. Ulmschneider S., Muller-Vieira U., Mitrenga M., Hartmann R.W., Oberwinkler-Marchais S., Klein C.D., Bureik M., Bernhardt R., Antes I., and Lengauer T. J. Med. Chem. 48 (2005) 1796
29. Jagusch C., Negri M., Hille U.E., Hu Q., Bartels M., Jahn-Hoffmann K., Pinto-Bazurco Mendieta M.A.E., Biemel K., Rodenwaldt B., Müller-Vieira U., Schmidt D., Lauterbach T., Recanatini M., Cavalli A., and Hartmann R.W. Bioorg. Med. Chem. 18 (2008) 228
30. Lin D., Zhang L., Chiao E., and Miller L.W. Mol. Endocrinol.. 8 (1994) 391
31. Auchus R.J., and Miller W.L. Mol. Endocrinol. 13 (1999) 1169
32. Mathieu A.P., LeHoux J.-G., and Auchus R.J. Biochim. Biophys. Acta 1619 (2003) 291
33. Brooke A.M., Taylor N.F., Shepherd J.H., Gore M.E., Ahmad T., Lin L., Rumsby G., Papari-Zareei M., Auchus R.J., Achermann J.C., and Monson J.P. J. Clin. Endocrinol. Metab. 91 (2006) 2428
34. Lewis D.F., Lake B.G., and Dickins M. J. Enzyme Inhib. Med. Chem. 22 (2007) 1
35. Vaz R.J., Nayeem A., Santone K., Chandrasena G., and Gavai A.V. Bioorg. Med. Chem. Lett. 15 (2005) 3816